<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21813">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046512</url>
  </required_header>
  <id_info>
    <org_study_id>201310102</org_study_id>
    <secondary_id>CK000162-aim3</secondary_id>
    <nct_id>NCT02046512</nct_id>
  </id_info>
  <brief_title>Probiotics to Promote Intestinal Health</brief_title>
  <official_title>Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus
      GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in
      patients on broad spectrum antimicrobials.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in the composition of the intestinal flora with a focus on multidrug-resistant organisms (MDRO) in the intention to treat population (ITT).</measure>
    <time_frame>Outcome will be measured every 3 days after enrollment, at the time of discharge, and at 60 days post-discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Colonization of the gastrointestinal tract with C. difficile, vancomycin-resistant enterococci (VRE), multidrug-resistant Acinetobacter baumannii, and multidrug-resistant Pseudomonas. Colonization occurs when the subject acquires the above organism while in the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Communicable Diseases</condition>
  <condition>Infection</condition>
  <condition>Anti-Infective Agents</condition>
  <condition>Therapeutic Uses</condition>
  <condition>Pharmacologic Actions</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Culturelle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults â‰¥ 18 years old

          -  Admission to the non-ICU medical and surgical wards

          -  On broad spectrum antimicrobials with an anticipated length of stay of &gt;48 hours

        Exclusion Criteria:

          -  Pregnancy

          -  Non English speaking

          -  Expected to die within 7 days

          -  Unable or unwilling to consent

          -  HIV infection with a CD4 count &lt;200

          -  Neutropenia with an absolute neutrophil count less than 500 cells/ml (or expected to
             drop to less than 500)

          -  Clinically significant diarrhea or history of C. difficile infection in the last 3
             months

          -  History of VRE colonization and/or infection in the last year

          -  Transplant recipients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. 2012 Jan. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 Feb-. Available from http://www.ncbi.nlm.nih.gov/books/NBK92613/</citation>
    <PMID>22574332</PMID>
  </reference>
  <reference>
    <citation>Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012 Jul;55(2):216-23. doi: 10.1093/cid/cis386. Epub 2012 Apr 4.</citation>
    <PMID>22491338</PMID>
  </reference>
  <reference>
    <citation>Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011 Sep;66(9):1963-71. doi: 10.1093/jac/dkr242. Epub 2011 Jun 18. Review.</citation>
    <PMID>21685488</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
